



Used in Lieu of PTO/SB/08A/B
(Based on PTO 04-07 version)

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/589,823-Conf. #2434
				Filing Date	August 17, 2006
				First Named Inventor	Armin SCHNEIDER
				Art Unit	3735
				Examiner Name	Not Yet Assigned
				Attorney Docket Number	4266-0126PUS1
Sheet	1	of	2		

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
/J.P./	AA*	US-4,276,110	06-30-1981	Bilhorn	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	MM-DD-YYYY			
/J.P./	BA	WO-00/42073-A1	07-20-2000			✓
/J.P./	BB	WO-02/22166-A2	03-21-2002			✓

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/J.P./	CA	Orlinick et al., Cell Signal, Vol. 10, No. 8, pp. 543-551 (1998)	
	CB	Chicheportiche et al., The Journal of Biological Chemistry, Vol. 272, No. 51, pp. 32401-32410 (December 19, 1997)	
	CC	Han et al., Biochemical and Biophysical Research Communications, Vol. 305, pp. 789-796 (2003)	
	CD	Wiley et al., Cytokine & Growth Factor Reviews, Vol. 14, pp. 241-249 (2003)	
	CE	Saas et al., GLIA, Vol. 32, pp.102-107 (2000)	
	CF	Cleveland et al., Nature Reviews/Neuroscience, Vol. 2, pp.806-819 (November 2001)	
	CG	Ishigaki et al., Journal of Neurochemistry, Vol. 82, pp.576-584 (2002)	
	CH	Li et al., Science, Vol. 288, pp.335-339 (April 14, 2000)	
	CI	Mochizuki et al., Proc. Natl. Acad. Sci., USA, Vol. 98, No. 19, pp.10918-10923 (September 11, 2001)	
	CJ	Xu et al., Nature Medicine, Vol. 8, No. 6, pp. 600-606 (June 2002)	
	CK	Viswanath et al., The Journal of Neuroscience, Vol. 21, No. 24, pp.9519-9528 (December 15, 2001)	
	CL	Hartmann et al., Neurology, Vol. 58, pp.308-310 (January 2002)	
	CM	Leker et al., Brain Research Reviews, Vol. 39, pp.55-73 (2002)	
	CN	Zheng et al., Circulation, Vol. 104, pp.2158-2163 (2001)	
	CO	Bottiger et al., Heart, Vol. 82, pp.674-679 (1999)	
	CP	Safar, Circulation, Vol. 74, pp.IV-138-IV-153 (December 1986)	
	CQ	Hossmann, Resuscitation, Vol. 26, pp.225-235 (1993)	
	CR	Safar et al., Crit Care Med, Vol. 30, No. 4, pp.S140-S144 (2002)	
	CS	Kelsey et al., Am. J. Emerg. Med., Vol. 4, pp.72-86 (1986)	
	CT	Abramson et al., N. Eng. J. Med., Vol. 314, No. 7, pp.397-403 (February 13, 1986)	

Examiner Signature	Date Considered
--------------------	-----------------

Used in Lieu of PTO/SB/08A/B
(Based on PTO 04-07 version)

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/589,823-Conf. #2434
				Filing Date	August 17, 2006
				First Named Inventor	Armin SCHNEIDER
				Art Unit	3735
				Examiner Name	Not Yet Assigned
Sheet	2	of	2	Attorney Docket Number	4266-0126PUS1

/J.P./	CU	Kelsey et al., Controlled Clin Trials, Vol. 12, pp.525-545 (1991)	
	CV	Abramson et al., The New England Journal of Medicine, Vol. 324, No. 18, pp.1225-1231 (May 2, 1991)	
	CW	Compston et al., The Lancet, Vol. 359, pp.1221-1231 (April 6, 2002)	
	CX	Thompson et al., Proc Natl. Acad Sci., USA, Vol. 98, No. 20, pp.11650-11655 (September 25, 2001)	
	CY	Cannon et al., Proc Natl. Acad Sci., USA, Vol. 99, No. 5, pp.3228-3233 (March 5, 2002)	
	CZ	Kohler et al., Nature, Vol. 256, pp.495-497 (August 7, 1975)	
	CA1	Jakubowski et al., Journal of Cell Science, Vol. 115, No. 2, pp.267-274 (2002)	
	CB1	Kurreck, Eur. J. Biochem., Vol. 270, pp.1628-1644 (2003)	
	CC1	Eckstein, Antisense & Nucleic Acid Drug Development, Vol. 10, pp.117-121 (2000)	
	CD1	Hughes et al., Drug Discovery Today, Vol. 6, No. 6, pp.303-315 (March 2001)	
	CE1	Liang et al., Eur. J. Biochem., Vol. 269, pp.5753-5758 (2002)	
	CF1	Brummelkamp et al., Science, Vol. 296, pp.550-553 (April 19, 2002)	
	CG1	Acsadi et al., Human Gene Therapy, Vol. 7, pp.129-140 (January 20, 1996)	
	CH1	Quantin et al., Proc. Natl. Acad. Sci. USA, Vol. 89, pp.2581-2584 (April 1992)	
	CI1	Ragot et al., Nature, Vol. 361, pp.647-650 (February 18, 1993)	
	CJ1	Rabinowitz et al., Curr. Opin. Biotechnol., Vol. 9, No. 5, pp.470-475 (1998)	
	CK1	Federico, Curr. Opin. Biotechnol., Vol. 10, No. 5, pp.448-453 (1999)	
	CL1	Latchman, Gene, Vol. 264, No. 1, pp.1-9 (2001)	
	CM1	Kaneda et al., Molecular Therapy, Vol. 6, No. 2, pp.219-226 (August 2002)	
	CN1	Kaneda, Molecular Membrane Biology, Vol. 16, pp.119-122 (1999)	
	CO1	Kay et al., Nature Medicine, Vol. 7, No. 1, pp.33-40 (January 2001)	
	CP1	Somia et al., Nature Reviews, Vol. 1, p.91-99 (November 2000)	
	CQ1	van Deutekom et al., Neuromuscular Disorders, Vol. 8, pp.135-148 (1998)	
	CR1	Jaynes et al., Molecular and Cellular Biology, Vol. 6, No. 8, pp.2855-2864 (August 1986)	
	CS1	Gossen et al., Proc. Natl. Acad. Sci. USA, Vol. 89, pp.5547-5551 (June 1992)	
	CT1	Rossi et al., Pharmac. Ther., Vol. 50, pp.245-254 (1991)	
	CU1	Hampel et al., Nucleic Acids Research, Vol. 18, No. 2, pp.299-304 (1990)	
	CV1	Cao et al., The Journal of Neuroscience, Vol. 22, No. 13, pp.5423-5431 (July 1, 2002)	
	CW1	Mi et al., Molecular Therapy, Vol. 2, No. 4, pp.339-347 (October 2000)	
	CX1	Morris et al., Nature Biotechnology, Vol. 19, pp.1173-1176 (December 2001)	
	CY1	Park et al., Journal of General Virology, Vol. 83, pp.1173-1181 (2002)	
	CZ1	Emerich et al., Clin Pharmacokinet, Vol. 40, pp.105-123 (2001)	
	CA2	Siegal et al., Clin Pharmacokinet, Vol. 41, No. 3, pp.171-186 (2002)	
	CB2	Brenner et al., Nature Biotechnology, Vol. 18, pp.630-634 (June 2000)	
	CC2	Velculescu et al., Science, Vol. 270, pp.484-487 (October 20, 1995)	
	CD2	Audic et al., Genome Res., Vol. 7, pp.986-995 (1997)	
	CE2	Desplat-Jego et al., Journal of Neuroimmunology, Vol. 133 pp.116-123 (2002)	
	CF2	Petrovita et al., The Journal of Neuroscience, Vol. 24, No. 38, pp.8237-8244 (September 22, 2004)	
	CG2	Yepes et al., American Journal of Pathology, Vol. 166, No. 2, pp.511-520 (February 2005)	
	CH2	Adams et al., Principles of Neurology, 6th Ed., New York, pp.1898-1899 (Standard Text Book)	
	CI2	Remington, Pharmaceutical Science, Mack Publishing Co. (1999)	

References not provided

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

Examiner Signature	/Jennifer Pitrak/	Date Considered	11/13/2008
--------------------	-------------------	-----------------	------------